文献速递生殖医学妇科

卵巢刺激药物与不孕女性乳腺癌风险:系统综述与荟萃分析

Risk of breast cancer in women treated with ovarian stimulation drugs for infertility: a systematic review and meta-analysis.
PubMed 文献 · Fertil Steril · 2021-01-01

该系统综述与荟萃分析检索1990年至2020年1月的电子数据库,纳入报告不孕女性使用卵巢刺激药物后新发乳腺癌的队列研究。汇总20项研究显示,与未暴露对照相比,任何卵巢刺激药物均未显著增加乳腺癌风险(合并OR 1.03,95%CI 0.86–1.23,I²=88.41%,证据质量极低)。克罗米芬或促性腺激素单用或联用亦未见显著风险增加。

要点

  • 不孕女性使用任何卵巢刺激药物后乳腺癌风险无显著增加(合并OR 1.03,95%CI 0.86–1.23)。
  • 克罗米芬或促性腺激素单用或联用均未发现乳腺癌风险显著升高。
  • 证据质量极低,主要因非随机研究的偏倚风险和间接性。

核心结论

  • 不孕女性使用克罗米芬和促性腺激素与乳腺癌风险增加无关。

研究设计与样本

  • 系统综述与荟萃分析,检索1990年至2020年1月的电子数据库,纳入报告不孕女性使用卵巢刺激药物后新发乳腺癌的队列研究。
  • 暴露组为接受卵巢刺激药物的不孕女性,对照为未暴露的一般人群和未暴露的不孕女性。

主要发现

  • 与未暴露对照相比,任何卵巢刺激药物治疗的不孕女性乳腺癌风险无显著增加(合并OR 1.03,95%CI 0.86–1.23,20项研究,I²=88.41%,证据质量极低)。
  • 克罗米芬或促性腺激素单用或联用均未发现乳腺癌风险显著增加。

关键数值与推荐

  • 合并OR 1.03(95%CI 0.86–1.23),基于20项研究,I²=88.41%,证据质量极低。

临床怎么用

  • 为不孕女性咨询卵巢刺激药物的乳腺癌风险时,可告知当前证据未显示显著风险增加。
  • 需注意证据质量极低,应结合个体情况谨慎解读。

局限性

  • 证据质量极低,因非随机研究存在严重偏倚风险和间接性。
  • 研究间异质性高(I²=88.41%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the evidence addressing the association between the use of ovarian stimulation drugs and the risk of breast cancer. DESIGN: Systematic review and meta-analysis. SETTING: Not applicable. PATIENT(S): Women without any previous history of breast cancer undergoing ovarian stimulation. INTERVENTION(S): Electronic databases were searched from 1990 until January 2020. All cohort studies reporting new incidences of breast cancer in infertile women using ovarian stimulating drugs were included. Treated (exposed) infertile women were compared with the unexposed general population with unexposed infertile women as controls. MAIN OUTCOME MEASURE(S): New diagnosis of breast cancer within an infertile and general population after exposure to ovarian stimulation drugs. RESULT(S): Overall, the quality of evidence was very low because of the serious risk of bias and indirectness (nonrandomized studies). There was no significant increase in the risk of breast cancer among women treated with any ovarian stimulation drug for infertility compared with that in unexposed controls from the general population and the infertile population (pooled odds ratio 1.03, 95% Confidence interval 0.86 to 1.23, 20 studies, I2 = 88.41%, very low quality of evidence). Furthermore, no significant increase in the risk of breast cancer was found with the use of clomiphene citrate or gonadotropins, alone or in combination. CONCLUSION(S): The current study found that the use of clomiphene citrate and gonadotropins in infertile women was not associated with an increased risk of breast cancer.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Beebeejaun Y, Athithan A, Copeland TP, et al. Risk of breast cancer in women treated with ovarian stimulation drugs for infertility: a systematic review and meta-analysis. Fertil Steril. 2021. PMID: 34148584. doi:10.1016/j.fertnstert.2021.01.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。